A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder

Schizophrenia Research

Volumn 106, Issue 2-3, 2008, Pages 308-314

  Hanssens, Linda ^a   van Winkel, Ruud ^b,c   Wampers, Martien ^b   Van Eyck, Dominique ^b   Scheen, Andre ^a   Reginster, Jean Yves ^a   Collette, Julien ^a   Peuskens, Joseph ^b   De Hert, Marc ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Department of Psychiatry and Psychology   (Netherlands)

Author keywords

Adiponectin; Antipsychotic; Diabetes; Metabolic syndrome; Schizophrenia

Indexed keywords

ADIPONECTIN; AMISULPRIDE; CHOLESTEROL; CLOZAPINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCREENING; SEX; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; CLOZAPINE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; MALE; METABOLIC SYNDROME X; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA;

EID: 56149091425     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.09.008     Document Type: Article

References (64)

1. Allison D.B., and Casey D.E. Antipsychotic-induced weight gain: a review of the literature. Journal of Clinical Psychiatry 62 Suppl 7 (2001) 22-31
2. Allison D.B., Fontaine K.R., Heo M., Mentore J.L., Cappelleri J.C., Chandler L.P., Weiden P.J., and Cheskin L.J. The distribution of body mass index among individuals with and without schizophrenia. Journal of Clinical Psychiatry 60 4 (1999) 215-220
3. Ader M., Kim S.P., Catalano K.J., Ionut V., Hucking K., Richey J.M., Kabir M., and Bregman N. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 54 (2005) 862-871
4. Arner P. Free fatty acids-do they play a central role in type 2 diabetes?. Diabetes, Obesity and Metabolism 3 Suppl 1 (2001) S11-S19
5. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., Hotta K., Shimomura I., Nakamura T., Miyaoka K., Kuriyama H., Nishida M., Yamashita S., Okubo K., Matsubara K., Muraguchi M., Ohmoto Y., Funahashi T., and Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochemical and Biophysical Research Communication 257 (1999) 79-83
6. Bai Y.M., Chen J.Y., Yang W.S., Chi Y.C., Liou Y.J., Lin C.C., Wang Y.C., Su T.P., and Chou P. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. Journal of Clinical Psychiatry 68 (2007) 1834-1839
7. B-Bridge International, Inc. Human Adiponectin ELISA kit User Manual, 2002.
8. Berg A.H., Combs T.P., Du X., Brownlee M., and Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Medicine 7 (2001) 947-953
9. Berg A.H., Combs T.E., and Scherer P.E. ACRP/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends in endocrinology and metabolism 13 2 (2002) 84-89
10. Bergman R.N., and Ader M. Atypical antipsychotics and glucose homeostasis. Journal of Clinical Psychiatry 66 (2005) 504-514
11. Casey D.E. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. American Journal of Medicine, 118 Suppl 2 (2005) 15-22
12. Cohn T.A., Remington G., Zipurski R.B., Azad A., Connolly P., and Wolever T. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Canadian Journal of Psychiatry 51 6 (2006) 382-386
13. Cote M., Mauriege P., Bergeron J., Alméras M., Tremblay A., Lemieux I., and Després J.P. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. Journal of Clinical Endocrinology and Metabolism 90 3 (2005) 1434-1439
14. De Hert M., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., and Peuskens J. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophrenia Research 83 1 (2006) 87-93
15. De Hert M., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., and Peuskens J. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clinical Practice and Epidemiology in Mental Health 2 14 (2006) 10.1186/1745-0179-2-14
16. De Nayer A., De Hert M., Scheen A., Van Gaal L., and Peuskens J. Conference report: Belgian consensus on metabolic problems associated with second-generation antipsychotics. International Journal of Psychiatry and Clinical Practice 9 2 (2005) 130-137
17. Dekker J., Funahashi T., Nijpels G., Pilz S., Stehouwer C., Snijder M., Bouter L., Matsuawa Y., Shimomura I., and Heine R. Prognostic value of adiponectin for cardiovascular disease and mortality. Journal of Clinical Endocrinology and Metabolism 93 4 (2008) 1489-1496
18. Dufresne R. Weighing in: emergent diabetes mellitus and second-generation antipsychotics. The annals of Pharmacotherapy 41 (2007) 1725-1370
19. Elman I., Goldstein D.S., Eisenhofer G., Folio J., Malhotra A.K., Adler C.M., Pickar D., and Breier A. A mechanism of peripheral noradrenergic stimulation by clozapine. Neuropsychopharmacology 1 20 (1999) 29-34
20. Elman I., Goldstein D.S., Green A.I., Eisenhofer G., Folio J., Holmes C.S., Pickar D., and Breier A. Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: a comparison with clozapine and placebo. Neuropsychopharmacology 27 2 (2002) 293-300
21. Elmquist J., and Flier F. The fat-brain axis enters a new dimension. Science 304 (2004) 63-64
22. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26 (2003) 3160-3166
23. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Position statement on the diagnosis and classification of diabetes mellitus. Diabetes Care 31 Suppl 1 (2008) S55-S60
24. Expert Panel on Detection and Evaluation of Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
25. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith S.C., Stone N.J., For the Coordinating Committee of the National Cholesterol Education Program, Endorsed by the National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and and American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 2 (2004) 227-239
26. Guerre-Millo M. Adiponectin: an update. Diabetes and Metabolism 34 (2008) 12-18
27. Haupt D.W., and Newcomer J.W. Hyperglycemia and antipsychotic medications. Journal of Clinical Psychiatry 62 27 (2001) 15-26
28. Hara K., Yamauchi T., and Kadowaki T. Adiponectin: an adipokine linking adipocytes and type 2 diabetes in humans. Current Diabetes Reports 5 2 (2005) 136-140
29. Hennekens C., Hennekens A.C., Hollar D., and Casey D.E. Schizophrenia and increased risks of cardiovascular disease. American Heart Journal 150 6 (2005) 1115-1121
30. Homel P., Casey D., and Allison D.B. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophrenia Research 55 3 (2002) 277-284
31. Hosojima H., Togo T., Odawara T., Hasegawa K., Miura S., Kato Y., Kase A., Uchikado H., and Hirayasu Y. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia?. Journal of Psychopharmacology 20 (2006) 75-79
32. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., Iwahashi H., Kuriyama H., Ouchi N., Maeda K., Nishida M., Kihara S., Sakai N., Nakajima T., Hasegawa K., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Hanafusa T., and Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type2 diabetic patients. Arteriosclerosis, Thrombosis, and Vascular Biology 20 (2000) 1595-1599
33. Hug C., and Lodish H.F. The role of the adipocyte hormone adiponectin in cardiovascular disease. Current Opinion in Pharmacology 5 2 (2005) 129-134
34. Jin H., Meyer J.M., and Jeste D.V. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Annals of Clinical Psychiatry 14 1 (2002) 59-64
35. Jin H., Meyer J.M., and Jeste D.V. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophrenia Research 71 2-3 (2004) 195-212
36. Jin H., Meyer J.M., Mudaliar S., and Jeste D.V. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizoprenia Research 100 1-3 (2008) 70-85
37. Kroeze W.K., Hufeisen S.J., Popadak B.A., Renock S.M., Steinberg S., Ernsberger P., Jayathilake K., Meltzer H.Y., and Roth B.L. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28 (2003) 519-526
38. Lihn A.S., Pedersen S.B., and Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obesity Reviews 6 (2005) 13-21
39. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
40. Matsubara M., Maruako S., and Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. The journal of clinical endocrinology & metabolism 87 6 (2002) 2764-2769
41. Matsuda M., Shimomura I., Sata M., Arita Y., Nishida M., Maeda N., Kumada M., Okamoto Y., Nagaretani H., Nishizawa H., Kishida K., Komuro R., Ouchi N., Kihara S., Nagai R., Funahashi T., and Matsuzawa Y. Role of adiponectin in preventing vascular stenosis. The Journal of Biological Chemistry 277 40 (2002) 37487-37491
42. Matsuzawa Y., Funahashi T., Kihara S., and Shimomura I. Adiponectin and metabolic syndrome. Arteriosclerosis, Thrombosis and Vascular Biology. 24 1 (2004) 29-33
43. Matsuzawa Y. Adipocitokines and metabolic syndrome. Seminars in Vascular Medicine 5 (2005) 34-39
44. Matsuzawa Y. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Atherosclerosis Supplements 6 (2005) 7-14
45. Meier U., and Gressner A. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin and resistin. Clinical Chemistry 50 9 (2004) 1511-1525
46. Meyer J.M., and Koro C.E. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Research 70 1 (2004) 1-17
47. Murashita M., Kusumi I., Inoue T., Takahashi Y., Hosoda H., Kangawa K., and Koyama T. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 30 (2005) 106-110
48. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 Suppl 1 (2005) 1-93
49. Newcomer J.W. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. Journal of Clinical Psychiatry 68 suppl 1 (2007) 20-27
50. Newcomer J.W. Metabolic syndrome and mental illness. American Journal of Managed Care 13 Suppl 7 (2007) 170-177
51. Reynolds G.P., Zhang Z.J., and Zhang X.B. Association of antipsychotic drug-induced weight gain with 5-HT2C receptor gene polymorphism. Lancet 359 9323 (2002) 2086-2087
52. Richards A.A., Hickman I.J., Wang A.Y., Jones A.L., Newell F., Mowry B.J., Whitehead J.P., Prins J.B., and Macdonald G.A. Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia. Journal of Clinical Psychopharmacology 26 3 (2006) 232-237
53. Sato C., Yasukawa Z., Honda N., Matsuda T., and Kitajima K. Identification and adipocyte differentiation-dependent expression of the unique disialic acid residue in an adipose tissue-specific glycoprotein, adipo Q. Journal of Biological Chemistry 276 31 (2001) 28849-28856
54. Scheen A.J., and De Hert M. Drug-induced diabetes mellitus: the example of atypical antipsychotics. Revue Medicale de Liege 60 5-6 (2005) 455-460
55. Scheen A.J., and De Hert M. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes & Metabolism 33 3 (2007) 169-175
56. Sherer P.E., Wiliams S., Fogliano M., Baldini G., and Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. Journal of Biological Chemistry 270 (1995) 26746-26749
57. Sporn A.L., Bobb A.J., Gogtay N., Stevens H., Greenstein D.K., Clasen L.S., Tossell J.W., Nugent T., Gochman P.A., Sharp W.S., Mattai A., Lenane M.C., Yanovski J.A., and Rapoport J.L. Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study. Journal of the American Academy of Child and Adolescent Psychiatry 44 9 (2005) 925-933
58. Togo T., Kojima K., Shoji M., Kase A., Uchikado H., Katsuse O., Iseki E., and Kosaka K. Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study. International Clinical Psychopharmacology 19 (2004) 37-40
59. Tschoner A., Engl J., Laimer M., Kaser S., Rettenbacher M., Fleischhacker W.W., Patsch J.R., and Ebenbichler C.F. Metabolic side effects of antipsychotic medication. International Journal of Clinical Practice 61 8 (2007) 1356-1370
60. Van Winkel R., de Hert M., Van Eyck D., Hanssens L., Wampers M., Scheen A., and Peuskens J. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. Journal of Clinical Psychiatry, 67 10 (2006) 1493-1500
61. Van Winkel R., De Hert M., Wampers M., Van Eyck D., Hanssens L., Scheen A., and Peuskens J. Major changes in glucose metabolism including new-onset diabetes within 3 months after initiation or switch of atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry 69 (2008) 472-479
62. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., and Tataranni P.A. Hypoadiponectomia in obesity and type 2 diabetes: close association with insulinresistance and hyperinsulinemia. Journal of Clinical Endocrinology and Metabolism 86 (2001) 1930-1935
63. Wu M.K., Huang C.Y., Liou Y.J., Wang C.K., and Lee S.D. Glucose-insulin homeostasis, lipid profiles and GH-IGF-IGFBP axis in clozapine-treated schizophrenic obesity versus non-psychiatric obesity. International Journal of Obesity advance online publication (2007) 10.1038/sj.ijo.0803750
64. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., Mori Y., Ide T., Murakami K., Tsuboyama-Kasaoka N., Ezaki O., Akanuma Y., Gavrilova O., Vinson C., Reitman M.L., Kagechika H., shudo K., Yoda M., Nakano Y., Tobe K., Nagai R., Kimura S., Tomita M., Froguel P., and Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 7 (2001) 941-946